Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures - PubMed
- ️Wed Jan 01 1997
Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures
K Nogami et al. Brain Res. 1997.
Abstract
To clarify the role of platelet-activating factor (PAF) in glutamate neurotoxicity, in vitro experiments using primary neuronal cultures were performed. The anti-PAF immunoglobulin-G (aPAF-IgG) and the three PAF receptor antagonists (BN52021, CV6209, and E5880) were tested for their neuroprotective activity in primary neuronal cultures isolated from embryonic rat cerebral cortex. The cultured neurons were exposed to glutamate (1 mM) for 60 min. Twenty-four hours after this exposure, aPAF-IgG demonstrated evidence of protective effects against neuronal damage in a dose-dependent manner. Protective effects also were observed in cultures treated with the three PAF antagonists (P < 0.05 at 1 microg/ml aPAF-IgG, P < 0.01 at 100 microM BN52021, P < 0.05 at 10 nM CV6209 and P < 0.01 at 10 nM E5880). The Fura-2 assay was used to estimate whether low dosages of exogenous PAF affect cultured neurons. The cultured neurons were loaded with Fura-2/AM. After preincubation for 120 min, the Fura-2-loaded neurons were exposed to various concentrations of PAF for 60 min. By measuring the fluorescent intensity of the medium as representing the amount of Fura-2 released from damaged neurons, we detected an increased release of Fura-2, even at low doses of PAF (P < 0.01 at 10 nM PAF). We further studied PAF production by neurons in response to glutamate. The level of PAF measured in the medium exposed to glutamate was significantly higher than the level in the medium unexposed to glutamate (P < 0.05). Our results suggest an important role of PAF in glutamate neurotoxicity.
Similar articles
-
Platelet-activating factor and cerebral vasospasm following subarachnoid hemorrhage.
Hirashima Y, Endo S, Otsuji T, Karasawa K, Nojima S, Takaku A. Hirashima Y, et al. J Neurosurg. 1993 Apr;78(4):592-7. doi: 10.3171/jns.1993.78.4.0592. J Neurosurg. 1993. PMID: 8450333
-
Xu Y, Tao YX. Xu Y, et al. Neuroreport. 2004 Feb 9;15(2):263-6. doi: 10.1097/00001756-200402090-00010. Neuroreport. 2004. PMID: 15076749
-
Ahlemeyer B, Krieglstein J. Ahlemeyer B, et al. Pharmacopsychiatry. 2003 Jun;36 Suppl 1:S8-14. doi: 10.1055/s-2003-40454. Pharmacopsychiatry. 2003. PMID: 13130383 Review.
-
Kulikov VI, Muzia GI. Kulikov VI, et al. Vestn Akad Med Nauk SSSR. 1991;(10):13-7. Vestn Akad Med Nauk SSSR. 1991. PMID: 1801455 Review. Russian.
Cited by
-
Efficacy of Ginkgolide B in the prophylaxis of migraine with aura.
D'Andrea G, Bussone G, Allais G, Aguggia M, D'Onofrio F, Maggio M, Moschiano F, Saracco MG, Terzi MG, Petretta V, Benedetto C. D'Andrea G, et al. Neurol Sci. 2009 May;30 Suppl 1:S121-4. doi: 10.1007/s10072-009-0074-2. Neurol Sci. 2009. PMID: 19415441 Clinical Trial.
-
Yamanaka G, Kanou K, Takamatsu T, Takeshita M, Morichi S, Suzuki S, Ishida Y, Watanabe Y, Go S, Oana S, Kawashima H. Yamanaka G, et al. J Clin Med. 2021 Jan 3;10(1):138. doi: 10.3390/jcm10010138. J Clin Med. 2021. PMID: 33401551 Free PMC article. Review.
-
Gingkolide B as migraine preventive treatment in young age: results at 1-year follow-up.
Usai S, Grazzi L, Bussone G. Usai S, et al. Neurol Sci. 2011 May;32 Suppl 1(Suppl 1):S197-9. doi: 10.1007/s10072-011-0522-7. Neurol Sci. 2011. PMID: 21533745 Free PMC article. Clinical Trial.
-
Lordan R, Tsoupras A, Zabetakis I, Demopoulos CA. Lordan R, et al. Molecules. 2019 Dec 3;24(23):4414. doi: 10.3390/molecules24234414. Molecules. 2019. PMID: 31816871 Free PMC article. Review.
-
An innovative approach for migraine prevention in young age: a preliminary study.
Usai S, Grazzi L, Andrasik F, Bussone G. Usai S, et al. Neurol Sci. 2010 Jun;31 Suppl 1(Suppl 1):S181-3. doi: 10.1007/s10072-010-0321-6. Neurol Sci. 2010. PMID: 20464618 Free PMC article.